Perhaps another reason rhAPC failed to show superiority to placebo in PROWESS-SHOCK is that overall care of patients with sepsis has improved, and studies conducted today to determine if a treatment is beneficial require ever larger numbers of enrollees just to show minimal differences. Abraham noted that when he began his medical training, sepsis mortaliBoston—Recent measles outbreaks in the United States and elsewhere are raising a number of questions about vaccination against this infection, such as the efficacy of current immunization schedules and the high costs of treating infected individuals. At the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) held here in late October, investigators gave several glimpses of the impact that outbreaks have had in different regions in 2011.ty rates were 70% and that rates were around 50% when rhAPC was approved in 2001; today, the death rate is around 25%.
展开▼
